Trial Outcomes & Findings for A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants (NCT NCT06704763)
NCT ID: NCT06704763
Last Updated: 2026-05-26
Results Overview
PK: AUC0-inf of Orforglipron.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
27 participants
Primary outcome timeframe
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8
Results posted on
2026-05-26
Participant Flow
Participant milestones
| Measure |
Midazolam + Orforglipron + Quinidine
Participants received:
* Day -1: single dose of 0.2 milligram (mg) midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine twice daily (BID).
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
Overall Study
STARTED
|
27
|
|
Overall Study
Received at Least One Dose of Study Drug
|
27
|
|
Overall Study
COMPLETED
|
27
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Baseline characteristics by cohort
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
Age, Continuous
|
35.3 years
STANDARD_DEVIATION 9.3 • n=20 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
14 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
23 Participants
n=20 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
22 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
|
Region of Enrollment
United States
|
27 Participants
n=20 Participants
|
PRIMARY outcome
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: AUC0-inf of Orforglipron.
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron
Day 1
|
89.9 nanogram*hour per milliliter
Geometric Coefficient of Variation 30.4
|
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron
Day 8
|
79.1 nanogram*hour per milliliter
Geometric Coefficient of Variation 30.2
|
PRIMARY outcome
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: Cmax of Orforglipron.
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
PK: Maximum Observed Concentration (Cmax) of Orforglipron
Day 1
|
4.11 nanogram per milliliter
Geometric Coefficient of Variation 32.2
|
|
PK: Maximum Observed Concentration (Cmax) of Orforglipron
Day 8
|
3.06 nanogram per milliliter
Geometric Coefficient of Variation 39.6
|
SECONDARY outcome
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: AUC0-inf of Midazolam.
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam
Day -1
|
2.06 nanogram*hour per milliliter
Geometric Coefficient of Variation 41.7
|
|
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam
Day 7
|
2.73 nanogram*hour per milliliter
Geometric Coefficient of Variation 42.1
|
SECONDARY outcome
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: Cmax of Midazolam.
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
PK: Maximum Concentration (Cmax) of Midazolam
Day -1
|
0.725 nanogram per milliliter
Geometric Coefficient of Variation 35.2
|
|
PK: Maximum Concentration (Cmax) of Midazolam
Day 7
|
0.999 nanogram per milliliter
Geometric Coefficient of Variation 49.2
|
SECONDARY outcome
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: AUC0-inf of 1-Hydroxymidazolam (metabolite of Midazolam).
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam
Day 7
|
0.999 nanogram*hour per milliliter
Geometric Coefficient of Variation 38
|
|
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam
Day -1
|
0.676 nanogram*hour per milliliter
Geometric Coefficient of Variation 39.2
|
SECONDARY outcome
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7Population: All enrolled participants who received at least one dose of study drug and had evaluable PK data for this outcome.
PK: Cmax of 1-Hydroxymidazolam (metabolite of Midazolam).
Outcome measures
| Measure |
Midazolam + Orforglipron + Quinidine
n=27 Participants
Participants received:
* Day -1: single dose of 0.2 mg midazolam.
* Day 1: single dose of 1 mg orforglipron.
* Days 5 to 6: 200 mg quinidine BID.
* Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam.
* Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.
|
|---|---|
|
PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam
Day -1
|
0.224 nanogram per milliliter
Geometric Coefficient of Variation 39.6
|
|
PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam
Day 7
|
0.343 nanogram per milliliter
Geometric Coefficient of Variation 50.5
|
Adverse Events
200 mg Quinidine BID + 0.2mg Midazolam (Day 7)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study)
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
0.2 mg Midazolam (Day -1)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
1 mg Orforglipron (Days 1 to 4)
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
200 mg Quinidine BID (Days 5 to 6)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
200 mg Quinidine BID + 0.2mg Midazolam (Day 7)
n=27 participants at risk
Participants observed for adverse events during and after Quinidine and Midazolam on Day 7, and prior to Day 8 dosing were grouped under this arm.
|
200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study)
n=27 participants at risk
Participants observed for adverse events during and after Quinidine and Orforglipron on Day 8 were grouped under this arm.
|
0.2 mg Midazolam (Day -1)
n=27 participants at risk
Participants observed for adverse events during and after Midazolam on Day -1 and prior to Day 1 dosing were grouped under this arm.
|
1 mg Orforglipron (Days 1 to 4)
n=27 participants at risk
Participants observed for adverse events during and after Orforglipron on Day 1 and prior to Day 5 dosing were grouped under this arm.
|
200 mg Quinidine BID (Days 5 to 6)
n=27 participants at risk
Participants observed for adverse events during and after Quinidine on Days 5, 6 and prior to Day 7 dosing were grouped under this arm.
|
|---|---|---|---|---|---|
|
Cardiac disorders
Palpitations
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Eye disorders
Dry eye
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Eye disorders
Vision blurred
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
7.4%
2/27 • Number of events 2 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
11.1%
3/27 • Number of events 3 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Rectal tenesmus
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
General disorders
Chest discomfort
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 2 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Nervous system disorders
Headache
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
7.4%
2/27 • Number of events 2 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Nervous system disorders
Lethargy
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Nervous system disorders
Muscle contractions involuntary
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Psychiatric disorders
Euphoric mood
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
|
Vascular disorders
Phlebitis
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
3.7%
1/27 • Number of events 1 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
0.00%
0/27 • Day -1 through the end of study (Up To 21 days)
* All enrolled participants who received at least one dose of study drug. * As per the planned safety analyses, adverse event data were reported by days (i.e) Day -1 = 0.2 mg Midazolam; Days 1 to 4 = 1 mg Orforglipron; Days 5 to 6 = 200 mg Quinidine BID ; Day 7 = 200 mg Quinidine BID + 0.2 mg Midazolam; Day 8 to end of study = 200 mg Quinidine BID + 1 mg Orforglipron .
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60